Diffractive MIOLs provide better reading performance

Article

Post-op bilateral reading performance is significantly improved when using a multifocal intraocular lens (MIOL) with a diffractive component rather than a refractive multifocal or monofocal lens, according to a recent study.

Post-op bilateral reading performance is significantly improved when using a multifocal intraocular lens (MIOL) with a diffractive component rather than a refractive multifocal or monofocal lens, according to a recent study published in the Journal of Cataract & Refractive Surgery.

The study group, led by Dr Jorge Alió, Vissum-Instituto Oftalmológico de Alicante, Alicante, Spain, compared the bilateral reading performance within a 6-month follow up period after implantation with four different IOLs.

A total of 304 eyes of 152 patients underwent bilateral phacoemulsification and then implantation with one of four IOLs. The lenses used in the study were the Acri-Smart 48S monofocal, AcrySof Restor SN6AD3 apodized mutlifocal, Acri.LISA 366D diffractive multifocal and the ReZoom refractive mutlifocal. For comparison each patient’s bilateral reading performance was measured both with and without near correction and pre- and postoperatively with the Salzburg Reading Desk.

It was found that all groups demonstrated an improvement in uncorrected and corrected distance visual acuity after implantation of the IOLs. However, a significant improvement in uncorrected reading acuity was demonstrated in the groups that had been implanted with the apodized multifocal and diffractive multifocal lenses at 1 month and 6 months post-op. Additionally, the uncorrected reading speed of the study group was found to be much worse in patients implanted with the refractive multifocal lens in comparison with the monofocal lens implant at 1 month follow-up.

From the results it was concluded that MIOLs with a diffractive component offered the best option for post-op reading performance when compared with refractive multifocal and monofocal IOLs.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.